Olaparib and paclitaxel for 2nd line gastric cancer therapy
Olaparib and paclitaxel for 2nd line gastric cancer therapy
Innovative uses of kinase inhibitors in cancer
Comment: Ribociclib for breast cancer
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate
Highlights of ESMO 2016
Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer
What is the future of proton therapy in the UK and worldwide?
Custirsen shows no survival benefit in metastatic prostate cancer
Benefits of adjuvant chemo for soft tissue sarcoma patients
Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma
Cabozantinib over sunitinib for metastatic renal cell carcinoma
How can we improve the reliability and quality of cancer registries?